AU2020340934A1 - Methods and compositions for improving oncolytic virus infection for nonpermissive cancers - Google Patents

Methods and compositions for improving oncolytic virus infection for nonpermissive cancers Download PDF

Info

Publication number
AU2020340934A1
AU2020340934A1 AU2020340934A AU2020340934A AU2020340934A1 AU 2020340934 A1 AU2020340934 A1 AU 2020340934A1 AU 2020340934 A AU2020340934 A AU 2020340934A AU 2020340934 A AU2020340934 A AU 2020340934A AU 2020340934 A1 AU2020340934 A1 AU 2020340934A1
Authority
AU
Australia
Prior art keywords
oncolytic virus
transport inhibitor
nucleocytoplasmic transport
virus
cancer cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020340934A
Other languages
English (en)
Inventor
Douglas Grant Mcfadden
Mohammed Masmudur RAHMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arizona State University Downtown Phoenix campus
Original Assignee
Arizona State University
Arizona State University Downtown Phoenix campus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arizona State University, Arizona State University Downtown Phoenix campus filed Critical Arizona State University
Publication of AU2020340934A1 publication Critical patent/AU2020340934A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2020340934A 2019-09-02 2020-09-01 Methods and compositions for improving oncolytic virus infection for nonpermissive cancers Abandoned AU2020340934A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962894929P 2019-09-02 2019-09-02
US62/894,929 2019-09-02
US201962913667P 2019-10-10 2019-10-10
US62/913,667 2019-10-10
PCT/US2020/048932 WO2021046048A1 (en) 2019-09-02 2020-09-01 Methods and compositions for improving oncolytic virus infection for nonpermissive cancers

Publications (1)

Publication Number Publication Date
AU2020340934A1 true AU2020340934A1 (en) 2022-03-31

Family

ID=74853433

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020340934A Abandoned AU2020340934A1 (en) 2019-09-02 2020-09-01 Methods and compositions for improving oncolytic virus infection for nonpermissive cancers

Country Status (9)

Country Link
US (1) US12691151B2 (enExample)
EP (1) EP4025230B1 (enExample)
JP (2) JP2022546985A (enExample)
KR (1) KR20220054865A (enExample)
CN (1) CN114667154A (enExample)
AU (1) AU2020340934A1 (enExample)
CA (1) CA3152787A1 (enExample)
IL (1) IL290974A (enExample)
WO (1) WO2021046048A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202100305SA (en) 2018-07-13 2021-02-25 Univ Arizona State Methods of treating cancer with tnf expressing myxoma virus
WO2020033510A1 (en) 2018-08-08 2020-02-13 Arizona Board Of Regents On Behalf Of Arizona State University Method for improved poxvirus yields
CA3112788A1 (en) 2018-09-05 2020-03-12 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus platform to treat hematological cancer
CA3152787A1 (en) 2019-09-02 2021-03-11 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for improving oncolytic virus infection for nonpermissive cancers
CN114615988A (zh) 2019-09-02 2022-06-10 亚利桑那州立大学董事会 用黏液瘤病毒治疗癌症的新型溶瘤病毒平台
CN116077505B (zh) * 2023-01-17 2024-09-06 广东省人民医院 Kpt-330联合5-fu或奥沙利铂在抗胃癌肿瘤药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2431349A1 (en) 2002-06-06 2003-12-06 Xiao-Dan Yao Method of producing a recombinant virus
WO2004015118A1 (en) 2002-08-07 2004-02-19 Bavarian Nordic A/S Vaccinia virus host range genes to increase the titer of avipoxviruses
AU2003264144C1 (en) 2002-09-05 2009-12-17 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
DK2388315T3 (da) 2005-03-07 2014-08-25 Univ Western Ontario Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling
US20120100109A1 (en) * 2010-10-26 2012-04-26 Xiaoliu Zhang Method for increasing the replication of oncolytic HSVs in highly resistant tumor cells using mTOR pathway and PI3K inhibitors
WO2015103438A2 (en) * 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
WO2020033510A1 (en) 2018-08-08 2020-02-13 Arizona Board Of Regents On Behalf Of Arizona State University Method for improved poxvirus yields
CA3152787A1 (en) 2019-09-02 2021-03-11 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for improving oncolytic virus infection for nonpermissive cancers

Also Published As

Publication number Publication date
WO2021046048A1 (en) 2021-03-11
EP4025230A4 (en) 2023-10-04
JP2025028853A (ja) 2025-03-05
CA3152787A1 (en) 2021-03-11
US12691151B2 (en) 2026-07-28
JP2022546985A (ja) 2022-11-10
KR20220054865A (ko) 2022-05-03
EP4025230B1 (en) 2025-11-05
IL290974A (en) 2022-05-01
EP4025230A1 (en) 2022-07-13
US20220296660A1 (en) 2022-09-22
CN114667154A (zh) 2022-06-24

Similar Documents

Publication Publication Date Title
EP4025230B1 (en) Methods and compositions for improving oncolytic virus infection for nonpermissive cancers
Smee et al. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir
Anne Stetler et al. Mitochondrial biogenesis contributes to ischemic neuroprotection afforded by LPS pre‐conditioning
JP5674210B2 (ja) 治療的処置のための粘液腫ウイルスとラパマイシンの組み合わせの使用
Wu et al. Oncolytic Newcastle disease virus carrying the IL24 gene exerts antitumor effects by inhibiting tumor growth and vascular sprouting
US20090137661A1 (en) Plant derived compounds and compound formulae containing the same for the treatment of cervical cancer
Liu et al. Evaluation of the antiviral activity of oleanolic acid against nervous necrosis virus
US12398375B2 (en) Methods for improved poxvirus yields
US20250387443A1 (en) Enhancing oncolytic virotherapy with a combination of nuclear export inhibitor and myxoma virus activating cell death pathways
HK40076417A (en) Methods and compositions for improving oncolytic virus infection for nonpermissive cancers
US20250249056A1 (en) Cancer therapies comprising a nuclear export inhibitor and an oncolytic virus
CN115721654B (zh) 藜芦碱在制备抗冠状病毒的药物中的应用
CN117257914A (zh) 谷胱甘肽在制备预防或治疗家蚕核型多角体病毒病药物中的应用
CN115778952A (zh) 番木瓜生物碱在制备抗新冠病毒的药物中的应用
US11591616B1 (en) Apoptotic upregulation by myxoma virus expressing walleye dermal sarcoma virus orfC
CN120753343B (zh) 辣椒素在制备防治鱼类病毒感染的饲料添加剂和/或药物中的用途
Ismaeel et al. Phaleria macrocarpa Fruit Protein Aqueous Extract Affects Viral Entry, Virucidal Activity, and Progeny Release.
WO2006000814A2 (en) Improved anti-viral compositions
Liu et al. Oleanolic Acid (Oa) Anti-Nnv is Achieved by Inhibiting Nnv-Induced Apoptosis and Enhancing Innate Immunity
KR20180024382A (ko) 심근염 유발 콕사키바이러스 ｂ3 증식억제 물질 및 이의 추출방법, 그리고 이를 함유하는 심근염 예방 또는 치료용 약학 조성물
Holechek Lessons from Vaccinia Virus Post-Exposure Prophylaxis: Insights into Control of Diseases and Epidemics
Elrod et al. Department of Pharmaceutical and Biomedical Sciences University of Georgia, Athens, GA 30602
Rehm The poxvirus A35 protein promotes virulence by regulating the host adaptive immune response
HK1163175B (en) Use of a myxoma virus that does not express functional m135r for therapeutic treatment

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application